Quantifying the impact of NSAID-associated adverse events

American Journal of Managed Care

Volumn 19, Issue 14 SUPPL., 2013, Pages

  Fine, Michael ^a  

^a HealthNet   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ACUTE KIDNEY FAILURE; ADVERSE DRUG REACTION; ANALGESIA; ARTHRITIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CLINICAL PRACTICE; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HELP SEEKING BEHAVIOR; HOSPITALIZATION; HUMAN; LIMIT OF QUANTITATION; LOW BACK PAIN; MORBIDITY; MORTALITY; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION; ACUTE DISEASE; ADULT; AGED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASES; HEALTH INSURANCE; KIDNEY DISEASES; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; UNITED STATES; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CHRONIC PAIN; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PAIN; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84904268964     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-1146.
2. McCarberg B, Gibofsky A. Need to develop new nonsteroidal anti-inflammatory drug formulations. Clin Ther. 2012;34(9):1954-1963.
3. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594-606. (Pubitemid 32171634)
4. The State of Aging and Health in America 2013. Atlanta, GA:Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2013.
5. Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746-754. (Pubitemid 39372033)
6. Coxib and traditional NSAID Trialists' Collaboration. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779.
7. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531-539. (Pubitemid 40341332)
8. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? a systematic review. Br J Clin Pharmacol. 2007;63(2):136-147. (Pubitemid 46072098)
9. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-889. (Pubitemid 44627273)
10. Public health advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). US Food and Drug Administration website. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm150314.htm. Published April 7,2005. Accessed September 20, 2013.
11. International Association for the Study of Pain. What is the problem? http://www.iasp-pain.org/AM/Template.cfm?Section=Fact-Sheets3&Template=/CM/ ContentDisplay.cfm&ContentID=11783. Published 2010. Accessed October 1, 2013.
12. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: The National Academies Press; 2011.
13. Coda BA, Bonica JJ. General considerations of acute pain. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd ed. Hagerstown, MD: Lippincott Williams & Wilkins; 2001:222-240.
14. Agency for Healthcare Research and Quality. Medical expenditure panel survey. http://meps.ahrq.gov/mepsweb/index.jsp. Accessed October 1, 2013.
15. Jacobson L, Mariano AJ. General considerations of chronic pain. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain. 3rd ed. Hagerstown, MD: Lippincott Williams & Wilkins; 2001:241-254.
16. Health, United States, 2012: with special feature on emergency care. Hyattsville, MD: National Center for Health Statistics; 2013.
17. Decision Resources, LLC. Pain management study: acute pain. Burlington, MA. 2012.
18. Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann Epidemiol. 2013;23(2):80-86.
19. Roemer M. Health care expenditures for the five most common conditions of adults ages 40 to 64, 2009. http://meps.ahrq.gov/mepsweb/data-files/ publications/st382/stat382.pdf. Accessed September 2013.
20. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol. 2001;15(5):739-753. (Pubitemid 32982363)
21. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. 2000;43(4):917-924.
22. Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008;168(11):1219-1224 (Pubitemid 351831405)
23. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141-149.
24. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27(14):1657-1663. (Pubitemid 44025350)
25. Helin-Salmivaara A, Saarelainen S, Grönroos JM, et al. Risk of upper gastrointestinal events with the use of various NSAIDs: a case-control study in a general population. Scand J Gastroenterol. 2007;42(8):923-932. (Pubitemid 47037118)
26. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PloS Med. 2011;8(9):e1001098.
27. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005;53(2):185-197. (Pubitemid 40530158)
28. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66(1):76-84. (Pubitemid 29350448)
29. Rahme E, Joseph L, Kong SX, Watson DJ, Pellissier JM, LeLorier J. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs. Pharmacoeconomics. 2001;19(5, pt 2):577-588. (Pubitemid 32488745)
30. Medication guide for non-steroidal anti-inflammatory drugs (NSAIDs). US Food and Drug Administration website. http://www.fda.gov/downloads/drugs/ drugsafety/ucm089162.pdf. Accessed September 20, 2013.